Can I legally buy calcitonin-salmon in the EU online?

No. Calcitonin-salmon is not authorised in the EU, and selling it is illegal. Any online seller offering it is operating illegally. Purchasing from unlicensed sources exposes you to product quality risks and potential legal consequences. Stick to licensed pharmacies and prescribed medications.

Why did the EU withdraw calcitonin-salmon but the USA didn't?

The EMA concluded the cancer risk was unacceptable when safer alternatives exist. The FDA took a more permissive approach, restricting duration and indication instead of withdrawing it entirely. Both regulators saw the same data; they weighed the evidence differently based on their regulatory philosophy.

Is calcitonin-salmon still used anywhere in the world?

Yes. It remains approved and available in the USA (with restrictions), Canada, Japan, and several other countries. However, it is not authorised in the EU, Australia, or many other jurisdictions. Regulatory status varies by country.

What should I use instead of calcitonin-salmon for osteoporosis?

Speak to your doctor about bisphosphonates (like alendronate), denosumab, or bone-building agents like teriparatide. For acute bone pain, NSAIDs and other analgesics are standard. Each option has different benefits and risks; your physician will recommend based on your individual case.

Could calcitonin-salmon be re-approved in the EU in the future?

Unlikely without substantial new evidence overturning the 2013 cancer risk assessment. No new data has emerged to change the EMA's decision, and no manufacturer has applied for re-authorisation. The regulatory door remains closed.

Calcitonin-salmon legal status in the EU: what changed and why

Calcitonin-salmon is not authorised for use in the European Union. Once available as a nasal spray under the brand name Miacalcin, it was withdrawn from the EU market in 2013 after the European Medicines Agency (EMA) identified a small but significant increased risk of cancer with long-term use. Unlike the United States, where the FDA kept the drug available with restrictions, European regulators chose to remove it entirely. Today, it is not licensed, not sold, and not legal to prescribe in any EU member state. This decision reflects a different regulatory philosophy: the EMA prioritised long-term safety signals over short-term benefits, particularly for a condition where stronger alternatives exist.

The EU regulatory timeline: from approval to withdrawal

Calcitonin-salmon has a complex history in Europe. The nasal spray formulation was authorised and marketed throughout EU member states for decades, primarily for osteoporosis treatment. It was considered a legitimate therapeutic option, especially for managing bone pain from spinal fractures and for patients who couldn't tolerate other treatments.

That status changed dramatically in 2013. The EMA's Committee for Medicinal Products for Human Use (CHMP) conducted a risk-benefit assessment and concluded that the benefits no longer justified the risks. The driving factor was not new data, but a reassessment of existing evidence. Epidemiological studies and post-marketing surveillance had raised concerns about a modestly elevated cancer risk in long-term users — particularly breast, lung, and ovarian cancers. The absolute risk increase was small, but it was consistent across multiple studies.

In September 2013, the EMA formally recommended withdrawal of all calcitonin-salmon nasal spray authorisations across the EU. Member states were required to revoke their national marketing authorisations. By 2014, calcitonin-salmon was no longer available in any EU country.

Why the EU and US diverged

This decision set Europe apart from the United States, where the FDA took a different approach. Rather than withdrawing the drug entirely, the FDA in 2012 added a black box warning about cancer risk and instructed manufacturers to limit nasal spray use to short-term treatment only. The drug remained on the US market, but with significant restrictions on duration and indication.

The divergence reflects genuine philosophical differences in drug regulation:

The EMA approach: When safer alternatives are available for the same condition, a small cancer risk is not acceptable, even if the absolute number of cases is low.
The FDA approach: A restricted indication and shorter duration of use might preserve access for patients with specific, acute needs (like spinal fracture pain) where the benefit-risk ratio is favourable.

EU regulators concluded that bisphosphonates, denosumab, and teriparatide all offered stronger fracture prevention without the same cancer signal. For acute pain management, other analgesics were deemed adequate. There was no clinical scenario, in their view, where calcitonin-salmon remained the best choice.

Current legal status: what you need to know

Calcitonin-salmon is not authorised in the EU. This means:

No legal prescription: No physician in any EU member state can legally prescribe it.
No legal supply: Pharmacies cannot stock or dispense it.
No marketing: Manufacturers cannot advertise, promote, or sell it.
No exceptions: There are no special access routes, compassionate use programs, or named-patient exemptions for calcitonin-salmon in the EU.

If a patient in Germany, France, Spain, or any other EU country requests calcitonin-salmon, their doctor cannot provide it through legal channels. Attempting to source it through unlicensed sellers or from outside the EU and import it for personal use falls into a grey area—technically the patient may not face prosecution, but the product is contraband in the EU and carries enforcement risk.

The regulatory context: EMA and national authorities

The EMA does not directly regulate medicines in the EU; it centralises the authorisation process. Once a medicine is authorised through the EMA's centralised procedure, it is valid across all member states. However, member states retain enforcement authority. They monitor the supply chain, inspect pharmacies, and prosecute illegal distribution.

When the EMA recommended withdrawal in 2013, member state authorities (like the German BfArM, French ANSM, or UK MHRA) were required to revoke their existing authorisations. Some member states that had previously allowed calcitonin-salmon under national procedures also revoked those licences.

Today, no EU regulatory body will issue a new authorisation for calcitonin-salmon unless the manufacturer submits substantial new safety data that overturns the 2013 cancer risk assessment. This has not happened, and there is no indication it will.

Clinical context: why the withdrawal mattered less than it might have

The withdrawal of calcitonin-salmon in 2013 was significant from a regulatory perspective, but had surprisingly modest impact on clinical practice. By that time, calcitonin-salmon was already being displaced by more effective treatments.

The landmark PROOF trial (Prevent Recurrence of Osteoporotic Fractures) in 2000 showed a 33% reduction in spinal fractures with nasal calcitonin-salmon. However, that trial had a high dropout rate and was later critiqued for its methodology. Subsequent analyses suggested the effect was overstated. In contrast, bisphosphonates (like alendronate and risedronate) and denosumab (a monoclonal antibody) showed stronger, more consistent fracture reduction with clearer safety profiles.

Calcitonin-salmon's remaining niche was acute bone pain, particularly in spinal compression fractures. Some evidence suggests it has an analgesic effect independent of its bone effects. However, even here, NSAIDs, paracetamol, and opioids provided reasonable alternatives.

By 2013, most European specialists had already moved away from calcitonin-salmon as a first-line agent. The withdrawal was a formalisation of a clinical shift that was already underway.

What consumers and patients should know

If you live in the EU and have osteoporosis or bone pain, calcitonin-salmon is not available to you through legal channels. This is not a temporary shortage or a regional restriction—it is a permanent regulatory decision based on a formal safety assessment.

If you previously used calcitonin-salmon:

Your doctor should have discussed alternatives with you at the time. If not, ask. The first-line options now are:

Bisphosphonates (alendronate, risedronate, or zoledronic acid)
Denosumab (Prolia)
Bone-building agents like teriparatide or abaloparatide
Hormone replacement therapy (in appropriate cases)

Each has a different mechanism and risk-benefit profile. Your physician can help you choose based on your specific condition, bone density, and medical history.

If you see calcitonin-salmon advertised online or offered by unlicensed sellers:

This is illegal in the EU. The product may be counterfeit, contaminated, or genuine but imported illegally. Purchasing it exposes you to:

Legal risk (though enforcement against patients is rare)
Product quality and safety risk
Lack of medical supervision

Report illegal advertising to your national medicines regulator (e.g., the ANSM in France, the BfArM in Germany, or the MHRA in the UK).

Ongoing regulatory monitoring

The EMA does not routinely reconsider withdrawn medicines unless new data emerges. The cancer risk signal identified in 2013 has not been refuted or explained away by new research. If anything, long-term follow-up studies have reinforced the concern.

As of 2024, there are no published applications to re-introduce calcitonin-salmon to the EU market. No manufacturer has submitted a new dossier or requested a reconsideration. The regulatory door remains closed.

International context

Calcitonin-salmon's status varies significantly by country:

EU: Not authorised; withdrawn 2013.
USA: FDA-approved with black box warning; restricted to short-term use.
Canada: Health Canada approved; still available.
Japan: Approved and still in use.
Australia: Not approved; not available.

This patchwork reflects different regulatory philosophies and different assessments of the same underlying safety data. The EU made the most restrictive choice, the USA a middle ground, and some other countries allow it with minimal restriction.

Summary

Calcitonin-salmon is not legal in the EU. It was withdrawn in 2013 after the EMA determined that the increased cancer risk outweighed the benefits, especially given the availability of more effective alternatives. No marketing authorisation exists in any EU member state, and no legal path to prescribe, supply, or dispense it remains. Patients in the EU should work with their physicians to identify approved alternatives tailored to their specific condition.

Calcitonin-salmon legal status in the EU: the withdrawal and what it means